|
US6428782B1
(en)
*
|
1997-05-23 |
2002-08-06 |
Hadasit Medical Research Services And Development Ltd. |
Non-myeloablative tolerogenic treatment
|
|
US6558662B2
(en)
|
1997-11-14 |
2003-05-06 |
The General Hospital Corporation |
Treatment of hematologic disorders
|
|
EP1131093A4
(en)
*
|
1998-11-09 |
2002-05-02 |
Idec Pharma Corp |
TREATMENT OF HEMATOLOGICAL VILTIES ASSOCIATED WITH CIRCULATING TUMOR CELLS USING CHIMERIC ANTI-CD20 ANTIBODIES
|
|
US20040265285A1
(en)
*
|
1999-04-15 |
2004-12-30 |
Monash University |
Normalization of defective T cell responsiveness through manipulation of thymic regeneration
|
|
US20050042679A1
(en)
*
|
1999-04-15 |
2005-02-24 |
Monash University |
Diagnostic indicator of thymic function
|
|
US20040258672A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Graft acceptance through manipulation of thymic regeneration
|
|
RU2165765C1
(ru)
*
|
2000-01-28 |
2001-04-27 |
Туманов Владимир Павлович |
Способ устранения травматического дефекта барабанной перепонки
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US7541184B2
(en)
*
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
|
US20060088512A1
(en)
*
|
2001-10-15 |
2006-04-27 |
Monash University |
Treatment of T cell disorders
|
|
WO2005021734A2
(en)
*
|
2003-09-02 |
2005-03-10 |
University Of Massachussets |
Generation of hematopoietic chimerism and induction of central tolerance
|
|
CA2539716A1
(en)
*
|
2003-09-22 |
2005-04-07 |
Xcyte Therapies, Inc. |
Compositions and methods to accelerate hematologic recovery
|
|
US20070269412A1
(en)
|
2003-12-02 |
2007-11-22 |
Celavie Biosciences, Llc |
Pluripotent cells
|
|
US20080279812A1
(en)
*
|
2003-12-05 |
2008-11-13 |
Norwood Immunology, Ltd. |
Disease Prevention and Vaccination Prior to Thymic Reactivation
|
|
EP1755685A4
(en)
*
|
2004-05-28 |
2008-11-12 |
Mayo Foundation |
METHODS FOR TRANSPLANTATION OF AUTOLOGOUS STEM CELLS
|
|
EP2345412A1
(en)
*
|
2005-12-02 |
2011-07-20 |
The Johns Hopkins University |
Use of high-dose oxazaphosphorine drugs for treating immune disorders
|
|
WO2008034071A2
(en)
*
|
2006-09-15 |
2008-03-20 |
The Johns Hopkins University |
Method of identifying patients suitable for high-dose cyclophosphamide treatment
|
|
WO2008034074A2
(en)
|
2006-09-15 |
2008-03-20 |
The Johns Hopkins University |
Cyclosphosphamide in combination with anti-idiotypic vaccines
|
|
WO2008034076A2
(en)
|
2006-09-15 |
2008-03-20 |
The Johns Hopkins University |
Cyclophosphamide in combination with immune therapeutics
|
|
EP2201103B1
(fr)
*
|
2007-10-12 |
2012-06-27 |
Université Pierre et Marie Curie (Paris 6) |
Traitement de tumeurs par des preparations de lymphocytes t
|
|
US9026372B2
(en)
*
|
2007-11-21 |
2015-05-05 |
Accentia Biopharmaceuticals, Inc. |
Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
|
|
WO2009067699A2
(en)
*
|
2007-11-21 |
2009-05-28 |
Accentia Biopharmaceuticals, Inc. |
Methods for providing a system of care for an oxazaphosphorine drug regimen
|
|
WO2009094456A2
(en)
*
|
2008-01-22 |
2009-07-30 |
Johns Hopkins University |
Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
|
|
JP5848131B2
(ja)
|
2008-12-17 |
2016-01-27 |
アナログ デバイシス， インコーポレイテッド |
機械共振構造体を備える機器
|
|
US20100209399A1
(en)
*
|
2009-02-13 |
2010-08-19 |
Celavie Biosciences, Llc |
Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects
|
|
US8228127B2
(en)
*
|
2009-12-23 |
2012-07-24 |
Sand 9, Inc. |
Oscillators having arbitrary frequencies and related systems and methods
|
|
US8604888B2
(en)
*
|
2009-12-23 |
2013-12-10 |
Sand 9, Inc. |
Oscillators having arbitrary frequencies and related systems and methods
|
|
ES2686424T5
(es)
|
2010-05-04 |
2023-03-27 |
Yeda Res & Dev |
Inmunoterapia con células alogénicas redireccionadas
|
|
MX370404B
(es)
*
|
2011-12-22 |
2019-12-11 |
Yeda Res & Dev |
Uso de una terapia de combinación para inducir un injerto estable y a largo plazo.
|
|
US20160000811A1
(en)
|
2013-02-20 |
2016-01-07 |
Novartis Ag |
Treatment of graft versus host disease in transplant patients
|
|
IL298044B2
(en)
*
|
2013-10-08 |
2024-11-01 |
Immunogen Inc |
Dosing regimens of anti-FOLR1 immunoconjugate
|
|
US10800649B2
(en)
|
2016-11-28 |
2020-10-13 |
Analog Devices International Unlimited Company |
Planar processing of suspended microelectromechanical systems (MEMS) devices
|
|
EP3874027A4
(en)
*
|
2018-10-31 |
2022-08-10 |
Magenta Therapeutics, Inc. |
METHODS OF HEMATOPOIETIC STEM AND PROGENITOR CELL TRANSPLANTATION THERAPY
|
|
EP3873502A4
(en)
*
|
2018-11-01 |
2022-06-29 |
Children's Hospital Medical Center |
Reduced intensity conditioning with melphalan
|
|
US10843920B2
(en)
|
2019-03-08 |
2020-11-24 |
Analog Devices International Unlimited Company |
Suspended microelectromechanical system (MEMS) devices
|
|
WO2020232368A1
(en)
*
|
2019-05-16 |
2020-11-19 |
Children's Hospital Medical Center |
Methods for determining personalized full dose of melphalan in reduced intensity regimen prior to hematopoietic cell transplantation
|
|
US12594341B2
(en)
|
2020-06-14 |
2026-04-07 |
Shimon Slavin |
Multifunctional immunotherapeutic monoclonal antibody complexes and conjugates
|